Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised furosemide for exercise-induced cough and dyspnoea in interstitial lung disease
ACTRN12619001032145Phase 3Not yet recruiting
- Sponsor
- Hunter New England Health
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furosemide in interstitial lung disease (ILD), sponsored by Hunter New England Health. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
furosemide
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on ACTRN12619001032145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001032145.